Collazos J, Genolla J, Ruibal A
Department of Internal Medicine, Galdacano Hospital, Vizcaya, Spain.
Clin Nucl Med. 1993 Jan;18(1):56-9. doi: 10.1097/00003072-199301000-00014.
Carbohydrate antigen 50 (CA 50) is a tumor marker that increases in many malignancies, especially in carcinoma of the digestive tract. False-positive results occur in benign liver disease. The behavior of CA 50 in 86 cirrhotic patients was studied, with thorough clinical and laboratory evaluations. There were abnormal values in 75.6% of the patients without significant differences among the different Child's grades. Significant correlations with some liver tests were found, especially transaminases, and at lower degrees with cholestatic parameters. Despite the previously reported relation with cholestasis, especially in biliary diseases, the CA 50 serum levels of the authors' cirrhotic patients appeared to be more closely related to cytolysis, according to the results of several statistical tests, including multivariate analysis. Because of the percentage and the levels of the abnormal results, this antigen cannot be used as a tumor marker in cirrhotic patients. Cytolysis seems to have a pathogenetic role in the increase of CA 50, at least in cirrhosis.
糖类抗原50(CA 50)是一种肿瘤标志物,在许多恶性肿瘤中会升高,尤其是在消化道癌中。良性肝病会出现假阳性结果。对86例肝硬化患者的CA 50情况进行了研究,并进行了全面的临床和实验室评估。75.6%的患者CA 50值异常,不同Child分级之间无显著差异。发现CA 50与一些肝功能检查存在显著相关性,尤其是转氨酶,与胆汁淤积参数的相关性较低。尽管之前报道CA 50与胆汁淤积有关,尤其是在胆道疾病中,但根据包括多变量分析在内的多项统计测试结果,作者所研究的肝硬化患者的CA 50血清水平似乎与细胞溶解更为密切相关。由于异常结果的百分比和水平,该抗原不能用作肝硬化患者的肿瘤标志物。细胞溶解似乎在CA 50升高中具有致病作用,至少在肝硬化中如此。